GATA2 and myelodysplastic syndrome: However, recommending HSCT to GATA2-deficient patients is challenging due to the broad clinical spectrum, incomplete penetrance, poor genotype–phenotype correlation and the lack of predictive factors for progression to MDS or myeloid malignancies.